Research involving genetics and experimental frameworks indicates that the IL-23-IL-17 pathway contributes to the development of spondyloarthritis (SpA), and IL-17 inhibitors are key components of modern therapies [15]. The gene discussed is IL17A; the disease is spondyloarthropathy.